featured-image

As of May 8, 2024, 156 subjects with advanced solid tumor were treated in phase 1 study. In 84 and 93mg/m2 dose optimal/expansion cohorts (including all advanced solid tumor subjects), 3.5% (2/57) and 3.

9% (2/51) subjects experienced dose reduction, and 5.3% (3/57) and 13.7% (7/51) subjects experienced study drug interruption, respectively.



No study treatment related death, and no ILD/pneumonitis and keratitis, uveitis, decreased vision was reported in this study. The major TRAEs were hematological toxicity. The dosages of 84 and 93 mg/m2 were selected in dose optimal study, the incidences of ≥ Grade 3 thrombocytopenia and neutropenia were 9% vs 28% and 19% vs 37%, respectively.

To the date of data cut-off, 54 subjects with platinum refractory or platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer were treated with BAT8006 doses of 1.8~2.4 mg/kg and 84/93mg/m2 and have received at least one tumor assessment.

Among these patients, 38.9% (21/54) of them had undergone>3 lines prior systemic treatment. Regardless of the FRα expression, the ORR including unconfirmed partial response (PR) is 37.

0% (20/54). In subjects with FRα<50%, FRα ≥50% and FRα ≥75%, the ORR is 33.3% (7/21), 39.

4% (13/33) and 46.7% (7/15), respectively. With a median follow up of 6.

5 months (1.3, 18.0 months), the median duration of response (mDOR) was 6.

3 months (1.8-16.5months).

The median progression free survival (mPFS) was 7.47 months (4.27~NA).

The overall survival.

Back to Health Page